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Abstract
Background: Efavirenz, widely used as part of antiretroviral drug regimens in the treatment of paediatric human
immunodeficiency virus infection, has central nervous system side effects. We describe four children presenting
with serious, persistent central nervous system adverse events who were found to have elevated plasma efavirenz
concentrations as a result of carrying CYP2B6 single nucleotide polymorphisms, known to play a role in the metabolism
of EFV. None of the children had a CYP2B6 wildtype haplotype. We believe this is the first case of cerebellar dysfunction
associated with efavirenz use to be described in children.
Case presentation: Four black African children, between the ages of 4 and 8 years presenting between 1 and
20 months post-efavirenz initiation, are described. Cerebellar dysfunction, generalised seizures and absence
seizures were the range of presenting abnormalities. Plasma efavirenz levels ranged from 20-60 mg/L, 5–15 times
the upper limit of the suggested reference range. All abnormal central nervous system manifestations abated
after efavirenz discontinuation.
Conclusion: Efavirenz toxicity should always be considered in human immunodeficiency virus-infected children
with unexplained central nervous system abnormalities. Our findings further our understanding of the impact of
genetic variants on antiretroviral pharmacokinetics in children across various ethnic groups. Screening for
potential EFV-toxicity based on the CYP2B6 c.516 SNP alone, may not be adequate.
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Background
Efavirenz (EFV) is a potent non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) used as part of combination
antiretroviral (ARV) regimens in the treatment of paediatric
and adult human immunodeficiency virus (HIV) infection.
Central nervous system (CNS) complications associated
with EFV use have been well characterised in adults, but
are less commonly described in children. We report on four
children who presented with serious, persistent CNS ad-
verse effects attributed to EFV toxicity while receiving
standard recommended weight-based EFV dosing as per
South African guidelines. All four children were found to
have plasma EFV concentrations above the suggested
therapeutic range and carried CYP2B6 single nucleotide
polymorphisms (SNPs), CYP2B6 c.516G > T, CYP2B6
c.785A > G and CYP2B6 c.983 T > C, which are associ-
ated with reduced CYP2B6 function and decreased EFV
metabolism Table 1.
Case presentation
Case-1 [Generalised tonic-clonic seizures]
A 4-year-6-month-old black South African male with peri-
natal HIV infection presented with generalised tonic-
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clonic seizures, 3 months after initiation of EFV-based
antiretroviral treatment (ART).
The child’s initial ARV regimen, started at 5 months of
age, consisted of lamivudine (3TC), stavudine (d4T), and
lopinavir/ritonavir (LPV/r) twice daily (bd). At 4 years of
age he was enrolled in a treatment strategy trial evaluat-
ing ART switches in virologically suppressed children
undertaken at Rahima Moosa Mother and Child Hos-
pital in Johannesburg, South Africa (ClinicalTrials.gov,
NCT01146873) [1]. Abacavir (ABC) was substituted for
d4T and LPV/r was switched to EFV 8 weeks thereafter.
EFV dosing was prescribed according to standard rec-
ommended weight-based dosing as per South African
guidelines [2]. Baseline assessment for neuropsychiatric
symptoms and neurological examination revealed no
abnormalities.
Three months post-EFV initiation, the child was hospi-
talised for seizures. The mother reported that the child
had multiple seizure episodes over a 3-day period with
pyrexia. No further information was provided. Lumbar
puncture (LP) showed no abnormalities and the child was
discharged the following day on an unknown oral anti-
biotic and paracetamol. After the episode, the mother de-
scribed the child’s behavior as becoming progressively
more aggressive; fighting with his siblings; defiant towards
his parents, but never violent. Routine clinical examina-
tions revealed no CNS abnormalities.
Ten months after switching to EFV, the child experi-
enced a generalised tonic-clonic seizure while being seen
at a routinely scheduled study visit. The seizure lasted
for approximately 1 minute, with no urination, tongue-
biting, hypersalivation or obvious postictal confusion.
The child had been seizure-free and clinically well since
his prior hospital admission. In addition to EFV-based
ART, tetryzoline (Spersallerg®) eye drops had been pre-
scribed for allergic conjunctivitis. No known allergies or
intolerances were reported.
After the witnessed seizure the child was hospitalised,
and investigations including a chest x-ray (CXR), urine
dipstick, septic blood work-up and LP revealed no abnor-
malities. The child was discharged the following day with
a diagnosis of idiopathic childhood epilepsy and started on
Table 1 Case detail summary
[Case 1]b [Case 2]b [Case 3]ab [Case 4]b











Event Described Generalised tonic-clonic
seizure
Cerebellar dysfunction Generalised tonic-clonic
seizure
Absence seizure
Sex Male Female Female Female
Starting ART Regimen LPV/r, 3TC, d4T LPV/r, 3TC, d4T LPV/r, 3TC, d4T RTV, 3TC, d4T
Age at ART start (months) 4.9 2.4 16.7 4
ART regimen at first event EFV, 3TC, ABC EFV, 3TC, ABC EFV, 3TC, ABC EFV, 3TC, d4T
Time on EFV at first event
(months)
3.3 19.8 13.7 0.9
Age at first event 4 years 6 months 4 years 10 months 7 years 6 months 4 years 7 months
EFV dose at first event
(mg/kg/dose)
21 mg/kg/dose 21 mg/kg/dose 15 mg/kg/dose 21 mg/kg/dose
Age at second event 5 years 4 years 11 months 9 years 5 months N/A
Time on EFV at second event
(months)
9.6 21.3 37.9 N/A
Time on EFV at time of drug
level (months)
10.1 23.5 49.7 1.2
EFV level mg/L (reference
range)
20 mg/L (1-4 mg/L) 60.54 mg/L (Ref > 1 mg/L) 51.23 mg/L (1-4 mg/L) 19.62 mg/L (1-4 mg/L)
Time since last dose prior to
levels (hours)
13 h post dose 13 h post dose 14 h post dose 15 h post dose
Genotype Heterozygous CYP2B6 516G/T
Heterozygous CYP2B6 785A/G
Heterozygous CYP2B6 516G/T
Heterozygous CYP2B6 983 T/C
Heterozygous CYP2B6 516G/T
Heterozygous CYP2B6 983 T/C
Homozygous CYP2B6
516 T/T
aNeverest 2 clinical trial (ClinicalTrials.gov, NCT00117728) [3] was a NVP-conserving strategy, aiming to preserve regimens for children exposed to NVP as part of
Prevention of Mother-to-Child Transmission (PMTCT). Children were either randomized to continue on a protease inhibitor (PI) or switch to NVP
bNeverest 3 clinical trial (ClinicalTrials.gov, NCT01146873) [1] evaluated PI-sparing treatment strategies among NVP-exposed HIV infected children initially treated
with lopinavir/ritonavir (LPV/r), but were either randomized to stay on LPV/r or switch to EFV
Abbreviations: LPV/r (lopinavir/ritonavir), 3TC (lamivudine), d4T (stavudine), EFV (efavirenz), RTV (ritonavir), ABC (abacavir), CYP2B6 (Cytochrome P450 2B6), G
(guanine), T (thymine), A (adenine), C (cytosine)
Pinillos et al. BMC Infectious Diseases  (2016) 16:56 Page 2 of 7
an antiepileptic drug (AED), sodium valproate, 15 mg/kg/
dose once daily (od). Outpatient electroencephalogram
(EEG) revealed no abnormalities and a contrast Computed
Tomography brain (CTB) scan showed normal develop-
mental structures, with no lesions or mass effect.
Plasma EFV levels were subsequently measured and
genotyping performed as part of clinical care in an attempt
to understand the nature of the presenting problem. The
plasma EFV level, 13 h post dose, was >20.0 mg/L (sug-
gested reference range: 1–4 mg/L) [3] as a result of the
genetic characterisation which showed the child to be het-
erozygous for both CYP2B6 c.516G/T and c.785A/G geno-
types. Consequently, EFV was discontinued and LPV/r
restarted. The AED was stopped after 7 weeks. No further
seizures have been reported, 30 months post-EFV discon-
tinuation, and the aggressive behavior has improved.
Case-2 [Cerebellar dysfunction]
A 4-year-10-month-old black Zimbabwean female with
perinatal HIV infection presented with clinical findings
consistent with cerebellar dysfunction, 20 months after
being switched to an EFV-based ART regimen.
She was initiated on 3TC, d4Tand LPV/r bd at 10 weeks
of age. Achieving and maintaining viral suppression, at
37 months of age she was enrolled in the same clinical trial
described above [1] and randomised to substitute ABC for
d4T and EFV for LPV/r 1 month thereafter. EFV dosing
was prescribed according to standard recommended
weight-based dosing as per South African guidelines [2].
Baseline assessment for neuropsychiatric symptoms and
neurological examination revealed no abnormalities.
Nineteen months after switching to EFV-based ART the
child presented with ataxia and tremors. The EFV dose
had been increased from 200 mg to 300 mg od 1 week
prior to presentation, as part of routine weight-based dose
adjustment. At this event, antibiotics were prescribed for a
urinary tract infection, and an outpatient CTB scheduled,
but was never performed.
Six weeks after the initial presentation the child was
noted as having progressively worsening ataxia, marked
upper and lower limb tremors and head bobbing. She
also complained of epigastric pain and post-prandial
vomiting. Examination on hospital admission revealed
an ataxic gait, titubation, dysarthria, intention tremor,
increased tone with cog-wheel rigidity in all limbs, and
truncal hypotonia. Power and reflexes in upper and
lower limbs were assessed as normal.
An urgent CTB scan revealed no abnormalities and a
follow-up Magnetic Resonance Imaging scan was within
normal limits. Laboratory findings including urea, electro-
lytes, full blood count, C-reactive protein (CRP) all re-
ported within normal limits, and blood culture results
showed no bacterial growth. Cerebrospinal fluid analysis
was within normal limits. Further investigations, including
screening for inborn errors of metabolism, were unable to
be carried out as the parents refused further hospital
admission.
Follow-up 2 months post-admission showed persist-
ence of the CNS signs and symptoms. At this time, EFV
toxicity was considered as a possible cause of the cere-
bellar dysfunction, drug levels and genotyping were ob-
tained and EFV was replaced with LPV/r.
Mid-dosing plasma EFV levels, taken 13 h post dose,
were reported at 60.54 mg/L (suggested reference range:
1-4 mg/L) [3] resulting from CYP2B6 genotyping, where
the child was found to be heterozygous carrying both
CYP2B6 c.516G/T and c.983 T/C genotypes.
Upon EFV discontinuation, significant improvement of
the cerebellar signs and symptoms was noted. Follow up
was for a period of 2 months, when the family relocated,
1 month of clinical observation with the caregivers
reporting continued clinical improvement telephonically
thereafter.
Case-3 [Generalised tonic-clonic seizures]
A 7-year-6-month-old black South African female
with perinatal HIV infection presented with general-
ised tonic-clonic seizures 14 months after starting an
EFV-based regimen.
The child was enrolled in an earlier trial at the same
site (ClinicalTrials.gov, NCT00117728) [4] and initiated
on 3TC, d4T and LPV/r at 17 months of age. Having
achieved viral suppression, she was randomised to sub-
stitute NVP for LPV/r 7 months after ART initiation.
The diagnosis of pulmonary tuberculosis necessitated
discontinuation of NVP and re-introduction of LPV/r at
age 3 years 10 months. She was subsequently enrolled in
a follow up trial [1] and at age 6 years 4 months, where
LPV/r was randomised to EFV. EFV dosing was pre-
scribed according to standard recommended weight-based
dosing as per South African guidelines [2]. Baseline assess-
ment for neuropsychiatric symptoms and neurological
examination revealed no abnormalities.
Thirteen months after starting EFV-based ART, the
child was hospitalised with generalised tonic-clonic sei-
zures and a suspected diagnosis of meningoencephalitis
and tonsillitis. Neurologically she had a diminished level
of consciousness (Glasgow coma scale of 10/15), menin-
gism, increased tone, and brisk reflexes globally. An ur-
gent CTB scan revealed no abnormalities. Besides an
elevated CRP, her blood and LP results were within nor-
mal limits. On reassessment the following day she was
awake, alert and fully cooperative with no meningism,
and normal tone and reflexes.
Anti-epileptic therapy, sodium valproate controlled re-
lease (CR) tablets 200 mg bd, were started and EFV was
continued. She was also discharged on paracetamol and
multivitamin. Sodium valproate CR was stopped when
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the prescription was inadvertently discontinued after
1 month.
The child was admitted 2 years later with her second
seizure episode having taken EFV-based ART for a 3-
year period. Although two further seizure episodes were
reported since her prior admission, no medical attention
had been sought. Seizures were described by the care-
giver as generalised tonic-clonic in nature accompanied
by urinary incontinence and a distinct postictal period.
On admission the child was apyrexial with a normal
physical examination except for enlarged uninfected ton-
sils. An elevated CRP and white blood cell count were
noted, but other investigations were within normal
limits. No LP was performed. She was restarted on anti-
convulsants, but defaulted treatment after 2 months. An
outpatient CTB was found to be normal.
Plasma EFV concentration was measured as a suspected
cause of the seizure activity. Plasma EFV level, 14 h post-
dose, was 51.23 mg/L (suggested reference range 1-4 mg/
L) [3] as a result of CYP2B6 genotyping revealing hetero-
zygosity for CYP2B6 c.516G/T and c.983 T/C genotypes.
EFV was discontinued and replaced with LPV/r. Follow-
up, 14 months post EFV-discontinuation, has revealed no
abnormalities and no further seizures were reported.
Case-4 [Absence seizures]
As previously described by Strehlau et al., a 4-year-7-
month-old black South African female presented with
new onset absence seizures and behavioral changes
1 month after starting an EFV-based regimen [5].
Conclusions
For more than a decade, EFV, in combination with a non-
nucleoside reverse transcriptase inhibitor backbone, has
been recommended as part of the first-line ART regimen
for adults and children older than 3 years in South Africa
[2, 6–8]. EFV is an attractive drug for the management of
children infected with HIV owing to once-daily dosing,
high potency, child-friendly formulations, palatability, and
alignment with adult regimens. When compared to NVP
in a meta-analysis of adults and children on first-line ther-
apy, EFV was observed to result in fewer treatment discon-
tinuations despite some patients presenting with severe
CNS effects [9]. In addition to cutaneous side effects, EFV
is most commonly associated with early, mild, transient
nervous system side effects in both adults [3, 9–15] as well
as children [9, 12, 16]. Dizziness, headaches, nightmares
and difficulty sleeping, tend to resolve spontaneously
within the first month of treatment. Severe CNS adverse
events appear to be infrequent and are not well described
in children.
A number of cases of severe adverse CNS side effects
associated with EFV use in children have been reported. A
10-year-old girl experienced one episode of generalised
seizures 6 weeks after switching from a PI-based to an
EFV-based regimen. It was noted that the patient had a
strong family history of epilepsy, although she had not
previously experienced seizures. ART was not interrupted,
she was not initiated on anticonvulsants and the seizures
did not recur [17]. Another reported case of a 12-year-old
girl presenting with psychosis associated with long term
EFV use with genetic analysis showing a heterozygous
CYP2B6 c.516G/T genotype [18]. Two of the 33 children
(6 %) reported on in an EFV pharmacokinetics study, pre-
sented with adverse events, namely a psychotic reaction
and seizures, with no further details provided [19].
In this case series, we describe severe CNS adverse events
in four children between 4 and 8 years of age presenting be-
tween 1 and 20 months post-EFV initiation. In all four
cases the plasma EFV levels were substantially higher than
the upper limit of the therapeutic range (1–4 mg/L) [3].
Children in this series presented with a variety of abnormal
CNS signs and symptoms – absence seizures, generalised
seizures, and cerebellar dysfunction. We believe this is the
first case of cerebellar dysfunction associated with EFV
treatment to be described in a child. Furthermore, in three
of the cases, CNS sequelae manifested late, 3–20 months,
after switching to EFV. All four cases showed significant
improvement, and even resolution of the CNS abnormal-
ities, once EFV treatment was discontinued.
EFV is primarily metabolised by the CYP2B6 enzyme
and to a lesser extent by CYP3A5, CYP3A4, CYP2A6 and
CYP1A2 isoforms of the cytochrome P450 system in the
liver [20, 21]. The gene coding for CYP2B6 is highly poly-
morphic and the CYP2B6 c.516G > T SNPs [11, 21–32]
and CYP2B6 c.983 T > C SNPs [23, 25, 33–37] have been
reportedly associated with reduced EFV oral clearance
resulting in increased plasma EFV concentrations. The
single nucleotide variant CYP2B6 c.516 T is linked to a
CYP2B6 mRNA splice variant that lacks exons four to six
and consequently lower levels of functional CYP2B6
enzyme [24], while the CYP2B6 c.983C variant causes a
non-synonymous amino acid change from isoleucine to
threonine at position 328 in exon 7 and, thus, reduced
CYP2B6 activity [37]. Furthermore it is known that signifi-
cant differences in allele frequencies between different
populations exist, for example the frequency of the
CYP2B6 c.516 T allele ranges from 14 % in Koreans [38]
to 27–30 % in Caucasians [36], 49 % in Africans [39] and
62 % in Papua New Guineans [40]. The CYP2B6 c.983C
allele is, however, not observed in Asian or Caucasian in-
dividuals, but is present in 4–9 % of Africans and African-
Americans [41].
The child in case 4 was homozygous for CYP2B6
c.516 T/T which has been shown to be associated with
substantially decreased CYP2B6 mRNA expression and
therefore higher plasma EFV levels leading to an increased
risk of CNS toxicity [3]. In a study done by Swart et al.
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[36], the frequencies of CYP2B6 c.516G/T and T/T geno-
types among healthy, black South Africans were 0.48 and
0.13, respectively. In the same study 88 % of patients with
the CYP2B6 c.516 T/T genotype presented with plasma
EFV concentrations above the therapeutic range. A sig-
nificant number of South African HIV-infected patients
could potentially benefit from EFV dosage optimisation
or reduction.
Both children in cases 2 and 3 carried CYP2B6 c.516G/T
and c.983 T/C genotypes, and individuals with dual c.516G/
T – c.983 T/C heterozygosity are CYP2B6 slow metaboli-
sers, because CYP2B6 c.516 T and CYP2B6 c.983C variants
reside on mutually exclusive haplotypes. [42] Carriers of
both the CYP2B6 c.516 T and c.983C variants are more
likely to present with high plasma EFV levels and exhibit
poorer CNS responses [23, 25, 33, 37]. CYP2B6 c.983 T/C
and C/C genotypes are present in 5–11 % and 0–2 %, re-
spectively, of black South Africans [36]. Swart et al. [36],
reported on nine adult patients with both the c.516G/T and
c.983 T/C genotypes with an average plasma EFV concen-
trations >12 mg/L.
The child described in case 1 was heterozygous for
CYP2B6 c.516G > T and the CYP2B6 c.785A > G SNP.
Similar to other populations, CYP2B6 c.516G > T SNP is
in tight linkage disequilibrium with the c.785A > G SNP.
Genotyping for the c.785A > G SNP, which is located in
exon 5 of CYP2B6, is thus not necessary [43, 44]. Studies
have reported a gene-dose effect with EFV clearance
following the pattern T/T < G/T < G/G and EFV levels
following the pattern T/T > G/T > G/G [27, 29]. This
could explain the lower EFV level in this case, however,
genotyping for CYP2B6 c.983 T/C was not performed.
EFV use has been well studied in adult populations, but
less so among children where physiological changes may
further complicate drug metabolism. For example, hepatic
enzyme activity is increased between the ages of 1–4 years,
potentially impacting drug metabolism [45]. Findings from
Saitoh et al. [27], suggest that age may need to be consid-
ered when evaluating the impact of genetic variants on
antiretroviral pharmacokinetics in children.
With the increasing use of ART resulting in HIV be-
coming a chronic disease, and the extended duration
perinatally infected children will remain on treatment,
reducing long-term ART-related side effects is a priority.
A reduced EFV dose of 400 mg from 600 mg in adults
was found to be non-inferior with a modest improve-
ment in adverse events [46]. Similarly, an EFV pharma-
cokinetics study in Ugandan adults suggested that a
daily EFV dose of 300 mg may be adequate for individ-
uals carrying the CYP2B6 c.516 T/T genotype [47]. Ter
Heine et al. [28], showed that children carrying the
CYP2B6 c516G/G genotype had a 50–70 % probability of
developing sub-therapeutic EFV concentrations, pointing
towards the need for dose optimisation in both adults and
children. Cases 1, 2 and 3, as compared to case 4, carried
not only the CYP2B6 c. 516G > T SNP but additional het-
erozygous SNP’s conferring impaired CYP2B6 activity
resulting in higher plasma EFV concentrations. Thus,
screening for potential EFV-toxicity based on the CYP2B6
516 SNP alone would fail to predict the patients with se-
verely impaired EFV metabolism. We hypothesize that
genotype-assisted EFV dose optimisation could possibly
assist with a reduction in severe CNS toxicities. Both
CYP2B6 c.516G > T and c.983 T > C SNP’s should be con-
sidered in predicting EFV plasma levels pronounced
effects, in decreasing the enzyme activity and frequencies
of the allelic variants among African populations. While
further research characterising the full spectrum of ad-
verse events associated with EFV are needed, clinical vigi-
lance and a high level of suspicion with any reported
neurobehavioral or CNS abnormalities for children receiv-
ing EFV-based regimens are needed.
Consent
Genetic characterization was performed as part of the
clinical evaluation in each case. Verbal informed con-
sent was obtained from patients’ caregivers before test-
ing. Written informed consent was obtained from all
patients’ caregivers to collate and publish information
found in this case report. A copy of the written consent
is available for review by the editor of this journal.
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